安斯泰来制药集团宣布，与Vir Biotechnology, Inc.达成一项合作协议。根据协议，Vir Biotechnology将获得总计3.35亿美元的款项，其中包括首付款以及近期可达成的里程碑付款。
此外，双方约定将平等分摊其合作产品在美国市场的利润与亏损。这一合作模式旨在平衡双方的风险与收益，共同推进相关产品的开发与商业化进程。
安斯泰来制药集团宣布，与Vir Biotechnology, Inc.达成一项合作协议。根据协议，Vir Biotechnology将获得总计3.35亿美元的款项，其中包括首付款以及近期可达成的里程碑付款。
此外，双方约定将平等分摊其合作产品在美国市场的利润与亏损。这一合作模式旨在平衡双方的风险与收益，共同推进相关产品的开发与商业化进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.